Close Menu

financial guidance

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected. 

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.

The firm reported revenues of $13.6 million and raised full-year revenue guidance, but revised full-year earnings guidance downward.

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

Pages

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.